TPP-1

TPP-1 is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity ( K D =95 nM). TPP-1 inhibits human tumor growth in vivo via reactivating T-cell function. In Vitro TPP-1 binds to PD-L1 with high affinity and blocks PD-1/PD-L1 interaction. The K D value of PD-L1 with TPP-1 peptide is about 95 nmol/L (around five times less than that with PD-1), The binding site of TPP-1 to PD-L1 is close to the interactive site of PD-1 and PD-L1. TPP-1 (4 μM) reactivates T-cell functions, it induces IFNγ release significantly higher than control and SPP-1, and the TPP-1 group shows similar outcomes for cell proliferation. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo TPP-1 (subcutaneous injection; 4 mg/kg; every other day eight times; 32 days) inhibits tumor growth (compared with SPP-1 and control). The growth rate in TPP-1-treated mice is 56%. And when administered in the absence of T cells (control group), TPP-1 has no effect on the growth of the H460-luc tumors . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: 5 to 6-week-old female Balb/c nude mice injected with H460 cells transfected with the plvx-puro/luciferase lentiviral vector Dosage: 4 mg/kg Administration: Subcutaneous injection; 4 mg/kg; every other day eight times; 32days Result: Inhibited the tumor growth in a tumor xenograft model via reactivating T-cell function. Form:Solid

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet